Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria.

Craig I ColemanE R WeedaA KharatB BookhartW L Baker

Published in: Diabetic medicine : a journal of the British Diabetic Association (2019)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of end-stage renal disease and slow the progression of nephropathy, but they do not appear to decrease all-cause or cardiovascular mortality in people with Type 2 diabetes and proteinuria.

Keyphrases

angiotensin converting enzyme
angiotensin ii
end stage renal disease
chronic kidney disease
peritoneal dialysis
cardiovascular events
risk factors
type diabetes
binding protein
skeletal muscle
weight loss